Edaravone Injection

Edaravone is used in the management of acute ischemic stroke to reduce oxidative stress and neuronal damage caused by ischemia. It helps in preserving brain tissue, potentially improving neurological outcomes and reducing infarct size when administered early after stroke onset.

Edaravone is approved for the treatment of Amyotrophic Lateral Sclerosis (ALS), a neurodegenerative disease. It helps slow the progression of ALS by reducing oxidative damage to motor neurons, thus improving motor function and extending survival time.

Edaravone has neuroprotective properties and is used for patients suffering from conditions that involve oxidative damage to neurons. It helps reduce inflammation, protects against cell death, and supports the repair of damaged nerve cells in various neurological disorders.

This injection is used in conditions associated with excessive oxidative stress, which is common in neurodegenerative diseases like Parkinson's disease, Alzheimer's disease, and other chronic neuroinflammatory disorders, where it helps to reduce neuronal injury and improve overall brain function.

Edaravone is utilized to manage traumatic brain injury (TBI) by preventing secondary neuronal injury that occurs after the initial impact, thus promoting recovery and reducing long-term cognitive deficits.